Genetic testing company Counsyl Inc. raised $28 million in a Series D investment, the company said Thursday, part of a wave of genetic testing companies hoping to screen potential parents and others for cancer and other diseases. The financing was co-led by Rosemont Seneca Technology Partners and Goldman Sachs Asset Management. Among the tests South San Francisco’s Counsyl is offering is screening for the BRCA1 and BRCA2 variants, which play a role in breast, ovarian, prostate and pancreatic cancers.
Help employers find you! Check out all the jobs and post your resume.
